Natera (NTRA) Reports Q2: Everything You Need To Know Ahead Of Earnings

Genetic testing company Natera (NASDAQ:NTRA) will be announcing earnings results this Thursday afternoon. Here’s what investors should know.

Natera beat analysts’ revenue expectations last quarter, reporting revenues of $696.6 million, up 38.8% year on year. It was a satisfactory quarter for the company, with a significant miss of analysts’ EPS estimates.

Is Natera a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Natera’s revenue to grow 21.2% year on year, slowing from the 32.2% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Natera has a history of exceeding Wall Street’s expectations.

Looking at Natera’s peers in the biotechnology segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Regeneron delivered year-on-year revenue growth of 16.7%, beating analysts’ expectations by 12.4%, and Incyte reported revenues up 37.7%, topping estimates by 11.3%. Regeneron traded up 9.7% following the results while Incyte was also up 6.9%.

Read our full analysis of Regeneron’s results here and Incyte’s results here.

Investors in the biotechnology segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Natera is down 1.7% during the same time and is heading into earnings with an average analyst price target of $282.86 (compared to the current share price of $278.86).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.